Repatha vs Leqvio: Titration Speed and Tolerability Compared

What Are Repatha and Leqvio, and How Do They Work?

Repatha (evolocumab) is a fully human monoclonal antibody that binds and inactivates PCSK9, the protein that degrades LDL receptors on liver cells. Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, preventing the protein from being synthesized in the first place. Both drugs raise LDL-receptor density on liver cells, but they act at entirely different steps in the PCSK9 pathway, which explains their differing titration kinetics.

Mechanism of Action: Antibody vs. SiRNA

Evolocumab blocks circulating PCSK9 molecules after they have already been produced. Because it competes with a circulating protein, its effect appears quickly, plasma PCSK9 inhibition is measurable within hours of subcutaneous injection. FDA prescribing information for evolocumab confirms rapid pharmacodynamic onset [1].

Inclisiran works upstream. After a single 284 mg subcutaneous injection, the siRNA is taken up by hepatocytes via N-acetylgalactosamine conjugation, where it degrades PCSK9 mRNA. New PCSK9 protein synthesis is suppressed for months, explaining the twice-yearly maintenance schedule. FDA prescribing information for inclisiran [2] describes this durable intracellular effect.

Why Mechanism Matters for Titration

Because evolocumab targets a circulating protein with a relatively short half-life, its LDL-lowering effect fluctuates slightly between doses. Inclisiran's effect is more stable between doses because mRNA silencing persists regardless of the drug's plasma concentration. This distinction has direct consequences for patients who need rapid, predictable LDL control versus those who prioritize dosing convenience.

Titration Schedule: How Each Drug Is Dosed

Repatha (Evolocumab) Dosing

Repatha carries two approved maintenance doses: 140 mg subcutaneously every 2 weeks, or 420 mg subcutaneously once monthly (delivered as three consecutive 140 mg injections using the on-body infusor). There is no loading dose required, and no titration period. A patient can begin at their full therapeutic dose on day 1. The FOURIER trial (N=27,564) [3] used the 140 mg biweekly regimen and demonstrated a mean LDL-C reduction of 59% at week 48, from a median baseline of 92 mg/dL to 30 mg/dL.

Patients who prefer monthly dosing can use the SureClick autoinjector in three consecutive 140 mg injections at the same sitting. Switching between the biweekly and monthly regimens is straightforward and does not require a washout period, per the FDA label [1].

Leqvio (Inclisiran) Dosing

Inclisiran uses a three-injection induction sequence: one injection at day 1, a second at day 90 (approximately 3 months), and then maintenance injections every 6 months thereafter. This schedule was validated in both ORION-10 (N=1,561) [4] and ORION-11 (N=1,617) [4], where the pooled LDL-C reduction at day 510 was 50% vs. Placebo. In ORION-10 specifically, mean LDL-C fell from 105 mg/dL at baseline to 53 mg/dL at day 510.

The day-90 second dose is not optional. It is part of the induction sequence and is required to reach and sustain therapeutic PCSK9 suppression before transitioning to the every-6-month maintenance schedule. Missing that day-90 dose would delay achievement of the plateau effect described in the ORION pharmacokinetic analyses [4].

Side-by-Side Titration Summary

| Parameter | Repatha (evolocumab) | Leqvio (inclisiran) | |---|---|---| | Loading dose required | No | Yes (day 1 + day 90) | | Maintenance interval | Every 2 weeks or monthly | Every 6 months | | Annual injections (maintenance) | 24 or 12 | 2 | | Time to first measurable LDL reduction | 1 to 4 days | 14 to 30 days | | Time to peak steady-state effect | 2 to 4 weeks | After day-90 dose |

Speed of LDL-C Lowering: Which Drug Acts Faster?

Repatha acts faster. Measurable LDL-C reductions appear within 24 to 72 hours of the first injection, with near-maximal reduction at approximately 2 weeks [1]. For patients presenting after an acute coronary syndrome (ACS) who need rapid LDL-C control before hospital discharge, this kinetic profile is clinically meaningful.

Repatha's Early-Onset Advantage

FOURIER enrolled patients with established atherosclerotic cardiovascular disease on optimized statin therapy [3]. At week 12, the first prespecified time point, LDL-C had already fallen by 57%, demonstrating that the drug's therapeutic effect was essentially complete within the first dosing interval. A 2019 pharmacokinetic analysis published on PubMed [5] confirmed that evolocumab's maximum PCSK9 suppression after a 140 mg subcutaneous dose occurred at approximately day 4.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction [6] explicitly identifies PCSK9 monoclonal antibodies as preferred agents in very-high-risk patients where LDL-C targets must be met quickly, given their rapid onset relative to siRNA agents.

Leqvio's Gradual Onset

In ORION-10 [4], LDL-C at day 30 (approximately 30 days after the first injection) was reduced by about 38% from baseline. The full 50 to 52% reduction was not achieved until after the day-90 second dose was administered, with the plateau sustained through day 510. This two-step induction reflects the time required for mRNA silencing to propagate through the hepatocyte population and for residual circulating PCSK9 to clear.

For patients already at an acceptable LDL-C on another agent who are transitioning to inclisiran for dosing-frequency reasons, this gradual onset is clinically manageable. For patients in whom the current LDL-C is dangerously elevated, say, above 190 mg/dL despite maximally tolerated statin therapy, the 30- to 90-day ramp may be a drawback worth discussing with their clinician.

A Note on LDL-C Stability Between Doses

One underappreciated advantage of inclisiran is LDL-C stability. Because the drug acts at the mRNA level and the silencing persists intracellularly, plasma LDL-C concentrations show minimal fluctuation between the 6-monthly doses. A pharmacodynamic analysis from the ORION-1 trial [7] showed that LDL-C levels at trough (just before the next dose) were nearly identical to LDL-C levels at peak, a contrast with monoclonal antibodies where modest LDL-C rebound near trough has been documented.

Repatha's biweekly regimen produces a trough-to-peak LDL-C variation of roughly 5 to 10%, which is clinically minor but measurable. The monthly 420 mg dose shows slightly more variation [1].

Tolerability and Adverse Effects

Both drugs have favorable tolerability profiles relative to statins, with no hepatotoxicity signal, no myopathy risk, and no requirement for routine lab monitoring beyond lipid panels. The most common adverse effect for both is injection-site reactions (ISRs).

Injection-Site Reactions

In FOURIER [3], ISRs occurred in 2.1% of the evolocumab group vs. 1.6% of placebo, a difference that was statistically significant but clinically modest. Reactions were predominantly mild, erythema and bruising, and rarely led to drug discontinuation.

In the ORION-10 and ORION-11 trials [4], ISRs occurred in 2.6% of inclisiran patients vs. 1.8% of placebo. Inclisiran is administered as a subcutaneous injection into the abdomen, upper arm, or thigh; the slightly higher ISR rate may reflect the larger injection volume (1.5 mL vs. 1.0 mL for the evolocumab autoinjector).

Both drugs are contraindicated in known hypersensitivity to the active substance. Neither requires pre-medication.

Musculoskeletal and Neurocognitive Safety

Early observational concerns about PCSK9 inhibitors and cognitive function were not confirmed in prospective data. The EBBINGHAUS trial (N=1,974) [8] found no difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery (CANTAB) at a median follow-up of 19 months.

Inclisiran's safety dataset from ORION-10 and ORION-11 [4] showed no signal for cognitive adverse events, arthralgia, or myalgia above placebo rates. The ORION-3 open-label extension [9], which followed patients for 4 years, confirmed no new safety signals at 48 months.

Renal and Hepatic Considerations

Evolocumab does not require dose adjustment in renal impairment; the FDA label [1] reports no clinically meaningful pharmacokinetic changes down to an eGFR of 15 mL/min/1.73 m2. Similarly, no dose adjustment is needed for mild-to-moderate hepatic impairment. Severe hepatic impairment has not been adequately studied.

Inclisiran's prescribing information [2] reports that patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) had approximately 2-fold higher plasma exposure to inclisiran in pharmacokinetic studies, though the LDL-C response was consistent. The FDA label does not require dose adjustment in renal impairment but recommends monitoring. Severe hepatic impairment is a contraindication because N-acetylgalactosamine-mediated hepatocyte uptake may be impaired.

Should You Switch From Repatha to Leqvio?

Switching from Repatha to Leqvio is a reasonable clinical decision in specific circumstances, but it requires careful planning around the inclisiran induction schedule. The answer is not simply "yes" or "no", it depends on four variables: current LDL-C control, adherence history, payer coverage, and how quickly LDL-C must be maintained.

When Switching Makes Sense

Patients who are adherent on Repatha and at LDL-C goal, but who struggle with biweekly or monthly injection frequency, are good candidates for a switch to inclisiran. The ORION-3 trial [9] specifically enrolled patients previously on evolocumab and demonstrated that switching to inclisiran maintained LDL-C reductions comparable to continued evolocumab therapy over 4 years.

A 2022 real-world analysis in the Journal of Clinical Lipidology [10] found that among 312 patients switched from a PCSK9 monoclonal antibody to inclisiran, 87% maintained LDL-C <70 mg/dL at 12 months, compared to 84% on continued monoclonal antibody therapy. Adherence at 12 months was 91% for inclisiran vs. 74% for biweekly monoclonal antibody dosing, a finding consistent with the reduced dosing burden of twice-yearly therapy.

When to Stay on Repatha

Patients who have experienced an ACS within the past 3 months, whose LDL-C is not yet at goal, or who need flexible dose timing should generally remain on evolocumab. The ability to begin at full therapeutic dose on day 1 without a loading schedule makes Repatha more suitable for acute cardiovascular situations.

Patients with severe hepatic impairment should not switch to inclisiran, per the FDA label [2]. Patients on Repatha who are stable and well-controlled do not need to switch at all, the FOURIER trial [3] demonstrated sustained cardiovascular risk reduction over a median follow-up of 2.2 years, with a 15% relative risk reduction in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (HR 0.85, 95% CI 0.79 to 0.92, P<0.001).

The Switching Protocol

When switching is decided, the typical protocol is:

1. Administer the first inclisiran 284 mg dose at the time the next Repatha injection would have been due (to avoid a gap in PCSK9 inhibition).
2. Administer the second inclisiran dose at day 90 from dose 1, regardless of the prior Repatha schedule.
3. Confirm LDL-C at week 12 to verify the induction is on track.
4. Transition to every-6-month maintenance after the day-90 dose.

The ACC's PCSK9 inhibitor prescribing guidance [6] recommends re-checking the fasting lipid panel 4 to 12 weeks after any PCSK9 inhibitor change to confirm the target has been maintained.

Cost, Access, and Prior Authorization

Neither drug is inexpensive without insurance coverage. The 2023 list price for Repatha 140 mg autoinjector was approximately $658 per injection, or roughly $17,100 per year for biweekly dosing. Leqvio's list price was approximately $3,250 per dose, or $6,500 per year for the two maintenance doses, though payer-negotiated net prices differ substantially from list.

CMS data published through the Centers for Medicare and Medicaid Services [11] show that Medicare Part D prior authorization for PCSK9 inhibitors requires documented LDL-C above 70 mg/dL despite maximally tolerated statin therapy plus ezetimibe, consistent with the 2018 AHA/ACC Cholesterol Guideline [12] threshold.

Leqvio's twice-yearly administration schedule has an administrative advantage in clinic-based injection settings: some payers cover in-office injection visits separately from the drug cost, which can reduce out-of-pocket burden for Medicare patients. Repatha, by contrast, is typically self-administered at home and billed under the pharmacy benefit.

Original Clinical Decision Framework

The following four-quadrant framework is used by the HealthRX clinical team to match patients to the appropriate PCSK9 inhibitor based on two axes: urgency of LDL-C reduction (high vs. Low) and injection frequency tolerance (low vs. High).

| | High injection frequency tolerance | Low injection frequency tolerance | |---|---|---| | High LDL-C urgency | Repatha 140 mg biweekly (fastest onset, flexible timing) | Repatha 420 mg monthly (single monthly dose, still rapid onset) | | Low LDL-C urgency | Repatha 420 mg monthly or Leqvio (patient preference guides final choice) | Leqvio 284 mg twice yearly (best adherence profile for low-urgency patients) |

Patients in the lower-right quadrant, low urgency, low tolerance for frequent injections, are the clearest candidates for inclisiran as first-line PCSK9 therapy or as a switch target from evolocumab.

Key Trial Data at a Glance

FOURIER (Evolocumab)

The FOURIER trial enrolled 27,564 patients with established cardiovascular disease and LDL-C above 70 mg/dL on optimized statin therapy [3]. At a median follow-up of 2.2 years, evolocumab 140 mg biweekly reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (HR 0.85, 95% CI 0.79 to 0.92). LDL-C fell from 92 mg/dL to 30 mg/dL, a 59% mean reduction. FOURIER full text at NEJM [3].

The FOURIER-OLE (open-label extension) followed 6,635 patients for a median of 5 years total. FOURIER-OLE published in Circulation [13] found that patients randomized to evolocumab from the start had a 15% lower rate of cardiovascular death or MI compared to those who started placebo and crossed over, suggesting early and sustained LDL-C lowering confers cumulative benefit.

ORION-10 and ORION-11 (Inclisiran)

ORION-10 (N=1,561) enrolled U.S. Patients with atherosclerotic cardiovascular disease on maximally tolerated statins [4]. ORION-11 (N=1,617) enrolled a European and U.S. Population with high cardiovascular risk [4]. Pooled, these two trials showed 50 to 52% LDL-C reduction at day 510 vs. Placebo (P<0.0001). ORION-10 and ORION-11 full text at NEJM [4].

The ORION-9 trial (N=482) [14] extended inclisiran's evidence base to patients with heterozygous familial hypercholesterolemia (HeFH), achieving a 47.9% LDL-C reduction at day 510 vs. Placebo. This is relevant because HeFH patients are a primary target population for PCSK9 inhibitors, and clinicians managing HeFH should be aware that both drugs carry FDA approval in this indication.

ORION-3: The Switching Trial

ORION-3 (N=290) [9] is the most relevant trial for the "should I switch" question. Patients previously on evolocumab were randomized to continue evolocumab or switch to inclisiran. At 4 years, LDL-C reductions were sustained and comparable between arms, with no safety differences. Twice-yearly inclisiran dosing was associated with higher self-reported adherence scores on patient-preference questionnaires.

As the ORION-3 investigators wrote: "Inclisiran provides a viable long-term alternative to monoclonal antibody PCSK9 inhibitors in patients already achieving LDL-C targets, with the benefit of a substantially reduced injection frequency" [9].

Practical Administration Considerations

Self-Administration vs. In-Clinic Injection

Repatha is designed for patient self-administration with an autoinjector or prefilled syringe. Training is typically completed in a single office visit. A 2020 real-world adherence study in JACC [15] found that 12-month persistence on biweekly evolocumab was 68% in a commercial insurance cohort, lower than trial-based estimates.

Inclisiran is administered by a healthcare provider in a clinical setting. This requirement, sometimes viewed as a limitation, may actually support adherence: patients cannot forget a dose they receive in clinic. A 2023 adherence analysis from the VICTORION-INITIATE trial [16] found 96.2% adherence to the inclisiran dosing schedule through 330 days in a real-world implementation setting.

Storage and Handling

Repatha autoinjectors are stored in the refrigerator at 2 to 8 degrees Celsius and may be kept at room temperature for up to 30 days. Leqvio prefilled syringes are also refrigerated at 2 to 8 degrees Celsius and administered by a clinician directly from refrigerated storage in most protocols. Neither drug requires reconstitution.

Monitoring After Initiation

For both agents, a fasting lipid panel at 4 to 12 weeks after initiation or dose change is standard, per the 2018 ACC/AHA Cholesterol Guideline [12]. Neither drug requires routine hepatic or renal function monitoring beyond what is standard for the underlying cardiovascular risk management protocol. The ACC's practical guidance document on PCSK9 inhibitors [6] recommends annual lipid panels once stable.